Skip to main content
. Author manuscript; available in PMC: 2020 Jun 19.
Published in final edited form as: Eur J Radiol. 2016 May 19;85(8):1383–1389. doi: 10.1016/j.ejrad.2016.05.008

Table 3:

Statistical comparison showing that MRA showed an equivalent incidence of actionable (Type 1) and non-actionable (Type 2+Type 3) findings to CTA.

CTA (Richman et al. [18]) cases/total %(95% CI) MRA This study cases/total % (95% CI) p-value
Type 1 (Actionable findings) 160/921

17% (15–20%)
85/514

17% (14–20%)
0.5
Types 2 and 3 (Non-actionable
findings or normal)
761/921

83% (80–85%)
429/514

83% (80–86%)
0.5